FRANKFURT (Reuters) - German healthcare conglomerate Fresenius SE & Co posted a 20 percent gain in first-half net income as its injectable generic drugs unit Kabi benefits from rivals' supply shortages. Fresenius, which failed to take over Rhoen-Klinikum, said adjusted net income in the first six months rose to 434 million euros ($534 million), broadly in line with the average estimate of 429 million in a Reuters poll among analysts. ... via Health News Headlines - Yahoo! News Read More Here..
Wednesday, 1 August 2012
Fresenius H1 net income up 20 percent on generic drugs
FRANKFURT (Reuters) - German healthcare conglomerate Fresenius SE & Co posted a 20 percent gain in first-half net income as its injectable generic drugs unit Kabi benefits from rivals' supply shortages. Fresenius, which failed to take over Rhoen-Klinikum, said adjusted net income in the first six months rose to 434 million euros ($534 million), broadly in line with the average estimate of 429 million in a Reuters poll among analysts. ... via Health News Headlines - Yahoo! News Read More Here..
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment